Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting

O Schnell, K Barnard, R Bergenstal, E Bosi, S Garg, B Guerci, T Haak, IB Hirsch, L Ji, SR Joshi, M Kamp, L Laffel, C Mathieu, WH Polonsky, F Snoek, P Home

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Thanks to significant improvements in the precision, accuracy, and usability of continuous glucose monitoring (CGM), its relevance in both ambulatory diabetes care and clinical research is increasing. In this study, we address the latter perspective and derive provisional reporting recommendations. CGM systems have been available since around the year 2000 and used primarily in people with type 1 diabetes. In contrast to self-measured glucose, CGM can provide continuous real-time measurement of glucose levels, alerts for hypoglycemia and hyperglycemia, and a detailed assessment of glycemic variability. Through a broad spectrum of derived glucose data, CGM should be a useful tool for clinical evaluation of new glucose-lowering medications and strategies. It is the only technology that can measure hyperglycemic and hypoglycemic exposure in ambulatory care, or provide data for comprehensive assessment of glucose variability. Other advantages of current CGM systems include the opportunity for improved self-management of glycemic control, with particular relevance to those at higher risk of or from hypoglycemia. We therefore summarize the current status and limitations of CGM from the perspective of clinical trials and derive suggested recommendations for how these should facilitate optimal CGM use and reporting of data in clinical research. © 2017, Mary Ann Liebert, Inc.
Original languageEnglish
Pages (from-to)391-399
Number of pages9
JournalDiabetes Technology and Therapeutics
Volume19
Issue number7
DOIs
Publication statusPublished - 2017

Fingerprint

Clinical Trials
Glucose
Ambulatory Care
Hypoglycemia
Self Care
Type 1 Diabetes Mellitus
Research
Hypoglycemic Agents
Hyperglycemia
Research Design
Technology

Cite this

Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. / Schnell, O; Barnard, K; Bergenstal, R; Bosi, E; Garg, S; Guerci, B; Haak, T; Hirsch, IB; Ji, L; Joshi, SR; Kamp, M; Laffel, L; Mathieu, C; Polonsky, WH; Snoek, F; Home, P.

In: Diabetes Technology and Therapeutics, Vol. 19, No. 7, 2017, p. 391-399.

Research output: Contribution to journalArticle

Schnell, O, Barnard, K, Bergenstal, R, Bosi, E, Garg, S, Guerci, B, Haak, T, Hirsch, IB, Ji, L, Joshi, SR, Kamp, M, Laffel, L, Mathieu, C, Polonsky, WH, Snoek, F & Home, P 2017, 'Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting', Diabetes Technology and Therapeutics, vol. 19, no. 7, pp. 391-399. https://doi.org/10.1089/dia.2017.0054
Schnell, O ; Barnard, K ; Bergenstal, R ; Bosi, E ; Garg, S ; Guerci, B ; Haak, T ; Hirsch, IB ; Ji, L ; Joshi, SR ; Kamp, M ; Laffel, L ; Mathieu, C ; Polonsky, WH ; Snoek, F ; Home, P. / Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. In: Diabetes Technology and Therapeutics. 2017 ; Vol. 19, No. 7. pp. 391-399.
@article{d0c009a403ee4425b0fa0031bc8c77ad,
title = "Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting",
abstract = "Thanks to significant improvements in the precision, accuracy, and usability of continuous glucose monitoring (CGM), its relevance in both ambulatory diabetes care and clinical research is increasing. In this study, we address the latter perspective and derive provisional reporting recommendations. CGM systems have been available since around the year 2000 and used primarily in people with type 1 diabetes. In contrast to self-measured glucose, CGM can provide continuous real-time measurement of glucose levels, alerts for hypoglycemia and hyperglycemia, and a detailed assessment of glycemic variability. Through a broad spectrum of derived glucose data, CGM should be a useful tool for clinical evaluation of new glucose-lowering medications and strategies. It is the only technology that can measure hyperglycemic and hypoglycemic exposure in ambulatory care, or provide data for comprehensive assessment of glucose variability. Other advantages of current CGM systems include the opportunity for improved self-management of glycemic control, with particular relevance to those at higher risk of or from hypoglycemia. We therefore summarize the current status and limitations of CGM from the perspective of clinical trials and derive suggested recommendations for how these should facilitate optimal CGM use and reporting of data in clinical research. {\circledC} 2017, Mary Ann Liebert, Inc.",
author = "O Schnell and K Barnard and R Bergenstal and E Bosi and S Garg and B Guerci and T Haak and IB Hirsch and L Ji and SR Joshi and M Kamp and L Laffel and C Mathieu and WH Polonsky and F Snoek and P Home",
year = "2017",
doi = "10.1089/dia.2017.0054",
language = "English",
volume = "19",
pages = "391--399",
journal = "Diabetes Technology and Therapeutics",
issn = "1520-9156",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting

AU - Schnell, O

AU - Barnard, K

AU - Bergenstal, R

AU - Bosi, E

AU - Garg, S

AU - Guerci, B

AU - Haak, T

AU - Hirsch, IB

AU - Ji, L

AU - Joshi, SR

AU - Kamp, M

AU - Laffel, L

AU - Mathieu, C

AU - Polonsky, WH

AU - Snoek, F

AU - Home, P

PY - 2017

Y1 - 2017

N2 - Thanks to significant improvements in the precision, accuracy, and usability of continuous glucose monitoring (CGM), its relevance in both ambulatory diabetes care and clinical research is increasing. In this study, we address the latter perspective and derive provisional reporting recommendations. CGM systems have been available since around the year 2000 and used primarily in people with type 1 diabetes. In contrast to self-measured glucose, CGM can provide continuous real-time measurement of glucose levels, alerts for hypoglycemia and hyperglycemia, and a detailed assessment of glycemic variability. Through a broad spectrum of derived glucose data, CGM should be a useful tool for clinical evaluation of new glucose-lowering medications and strategies. It is the only technology that can measure hyperglycemic and hypoglycemic exposure in ambulatory care, or provide data for comprehensive assessment of glucose variability. Other advantages of current CGM systems include the opportunity for improved self-management of glycemic control, with particular relevance to those at higher risk of or from hypoglycemia. We therefore summarize the current status and limitations of CGM from the perspective of clinical trials and derive suggested recommendations for how these should facilitate optimal CGM use and reporting of data in clinical research. © 2017, Mary Ann Liebert, Inc.

AB - Thanks to significant improvements in the precision, accuracy, and usability of continuous glucose monitoring (CGM), its relevance in both ambulatory diabetes care and clinical research is increasing. In this study, we address the latter perspective and derive provisional reporting recommendations. CGM systems have been available since around the year 2000 and used primarily in people with type 1 diabetes. In contrast to self-measured glucose, CGM can provide continuous real-time measurement of glucose levels, alerts for hypoglycemia and hyperglycemia, and a detailed assessment of glycemic variability. Through a broad spectrum of derived glucose data, CGM should be a useful tool for clinical evaluation of new glucose-lowering medications and strategies. It is the only technology that can measure hyperglycemic and hypoglycemic exposure in ambulatory care, or provide data for comprehensive assessment of glucose variability. Other advantages of current CGM systems include the opportunity for improved self-management of glycemic control, with particular relevance to those at higher risk of or from hypoglycemia. We therefore summarize the current status and limitations of CGM from the perspective of clinical trials and derive suggested recommendations for how these should facilitate optimal CGM use and reporting of data in clinical research. © 2017, Mary Ann Liebert, Inc.

U2 - 10.1089/dia.2017.0054

DO - 10.1089/dia.2017.0054

M3 - Article

VL - 19

SP - 391

EP - 399

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

IS - 7

ER -